Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CORBF NASDAQ:NAKA OTCMKTS:RNLXD NASDAQ:XGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCORBFGlobal Cord Blood$0.95$0.99$0.20▼$1.75$115.47M-0.81,778 shs2,619 shsNAKAKindlyMD$5.49-24.1%$0.49$5.48▼$1,180.00$95.53M17.12146,435 shs844,135 shsRNLXDRenalytix$1.19-6.0%$1.47$3.13▼$8.09$10.36M2.632,432 shs1,726 shsXGNExagen$4.62+8.5%$3.14$2.59▼$12.23$111.62M1.81448,012 shs412,121 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCORBFGlobal Cord Blood0.00%0.00%0.00%0.00%-5.00%NAKAKindlyMD0.00%+6.32%-15.93%-20.93%+722,999,900.00%RNLXDRenalytix0.00%-2.07%+7.73%-57.50%+118,499,900.00%XGNExagen0.00%+22.06%+57.78%+15.45%-35.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCORBFGlobal Cord Blood$0.95$0.99$0.20▼$1.75$115.47M-0.81,778 shs2,619 shsNAKAKindlyMD$5.49-24.1%$0.49$5.48▼$1,180.00$95.53M17.12146,435 shs844,135 shsRNLXDRenalytix$1.19-6.0%$1.47$3.13▼$8.09$10.36M2.632,432 shs1,726 shsXGNExagen$4.62+8.5%$3.14$2.59▼$12.23$111.62M1.81448,012 shs412,121 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCORBFGlobal Cord Blood0.00%0.00%0.00%0.00%-5.00%NAKAKindlyMD0.00%+6.32%-15.93%-20.93%+722,999,900.00%RNLXDRenalytix0.00%-2.07%+7.73%-57.50%+118,499,900.00%XGNExagen0.00%+22.06%+57.78%+15.45%-35.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCORBFGlobal Cord Blood 0.00N/AN/AN/ANAKAKindlyMD 2.40Hold$30.00446.45% UpsideRNLXDRenalytix 0.00N/AN/AN/AXGNExagen 2.78Moderate Buy$9.25100.22% UpsideCurrent Analyst Ratings BreakdownLatest RNLXD, NAKA, CORBF, and XGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026XGNExagen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026XGNExagen BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $8.005/11/2026NAKAKindlyMD Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/27/2026XGNExagen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026XGNExagen Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.004/10/2026NAKAKindlyMD TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.004/6/2026NAKAKindlyMD Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$60.00 ➝ $30.003/27/2026NAKAKindlyMD Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/11/2026XGNExagen UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.003/11/2026XGNExagen Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$15.00 ➝ $10.003/11/2026XGNExagen Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.00(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCORBFGlobal Cord BloodN/AN/AN/AN/AN/AN/ANAKAKindlyMD$1.82M52.49N/AN/A$21.09 per share0.26RNLXDRenalytix$3M3.45N/AN/A($1.06) per share-1.12XGNExagen$66.57M1.68N/AN/A$0.60 per share7.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCORBFGlobal Cord BloodN/AN/AN/AN/AN/AN/AN/AN/AN/ANAKAKindlyMD-$52.23M-$43.20N/AN/AN/A-7,397.12%-81.32%-54.17%N/ARNLXDRenalytix-$20.40M-$6.25N/AN/AN/AN/AN/AN/AN/AXGNExagen-$19.95M-$0.89N/AN/AN/A-29.49%-94.37%-28.96%8/4/2026 (Estimated)Latest RNLXD, NAKA, CORBF, and XGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026NAKAKindlyMDN/A-$15.20N/A-$0.38N/A$2.68 million5/11/2026Q1 2026XGNExagen-$0.24-$0.17+$0.07-$0.17$16.41 million$17.31 million3/10/2026Q4 2025XGNExagen-$0.20-$0.20N/A-$0.20$16.46 million$16.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCORBFGlobal Cord BloodN/AN/AN/AN/AN/ANAKAKindlyMDN/AN/AN/AN/AN/ARNLXDRenalytixN/AN/AN/AN/AN/AXGNExagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCORBFGlobal Cord BloodN/AN/AN/ANAKAKindlyMDN/A0.250.25RNLXDRenalytixN/A1.211.17XGNExagen1.673.473.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCORBFGlobal Cord BloodN/ANAKAKindlyMDN/ARNLXDRenalytix9.92%XGNExagen75.25%Insider OwnershipCompanyInsider OwnershipCORBFGlobal Cord Blood0.50%NAKAKindlyMD24.49%RNLXDRenalytix10.50%XGNExagen12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCORBFGlobal Cord Blood1,200121.55 million120.94 millionNot OptionableNAKAKindlyMDN/A17.40 million13.14 millionN/ARNLXDRenalytix1008.74 million7.82 millionOptionableXGNExagen22024.16 million21.12 millionOptionableRNLXD, NAKA, CORBF, and XGN HeadlinesRecent News About These CompaniesExagen Inc. (NASDAQ:XGN) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 19, 2026 | americanbankingnews.comExagen Earnings Call Highlights Growth Amid Key RisksMay 15, 2026 | theglobeandmail.comThe Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New ForecastsMay 15, 2026 | finance.yahoo.comExagen Inc. (NASDAQ:XGN) Q1 2026 Earnings Call TranscriptMay 13, 2026 | insidermonkey.comExagen Inc (XGN) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...May 12, 2026 | finance.yahoo.comExagen Inc. (XGN) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comRecord revenue growth and higher test pricing keep Exagen (XGN) in focus despite ongoing lossesMay 12, 2026 | msn.comExagen Q1 Earnings Call HighlightsMay 11, 2026 | marketbeat.comExagen (NASDAQ:XGN) Issues Earnings Results, Beats Estimates By $0.07 EPSMay 11, 2026 | marketbeat.comExagen Inc. (XGN) Reports Q1 Loss, Beats Revenue EstimatesMay 11, 2026 | zacks.comExagen Inc. Reports First Quarter 2026 ResultsMay 11, 2026 | globenewswire.comExagen (NASDAQ:XGN) Upgraded by Wall Street Zen to "Hold" RatingMay 9, 2026 | marketbeat.comZimmer Biomet (ZBH) Q1 Earnings and Revenues Top EstimatesApril 28, 2026 | zacks.comExagen Inc. to Announce First Quarter Financial Results on May 11, 2026April 27, 2026 | globenewswire.comExagen (XGN) to Release Quarterly Earnings on MondayApril 27, 2026 | marketbeat.comExagen Inc. (NASDAQ:XGN) Sees Large Decrease in Short InterestApril 26, 2026 | marketbeat.comExagen Announces Board Resignation and Committee RestructuringApril 23, 2026 | tipranks.comDoes Exagen (XGN)’s 200%+ Upside Potential Make It One of the Best Penny Stocks Set to Explode?April 12, 2026 | insidermonkey.comHow Analyst Resets Are Reshaping The Exagen (XGN) Investment StoryMarch 27, 2026 | finance.yahoo.comExagen (XGN) price target decreased by 21.78% to 10.03March 27, 2026 | msn.comExagen outlines $70M–$73M 2026 revenue target while expanding sales force and innovation cadenceMarch 11, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNLXD, NAKA, CORBF, and XGN Company DescriptionsGlobal Cord Blood OTCMKTS:CORBF$0.95 0.00 (0.00%) As of 03:34 PM EasternGlobal Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.KindlyMD NASDAQ:NAKA$5.49 -1.74 (-24.07%) As of 04:00 PM EasternKindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.Renalytix OTCMKTS:RNLXD$1.19 -0.08 (-5.95%) As of 05/22/2026Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.Exagen NASDAQ:XGN$4.62 +0.36 (+8.45%) As of 04:00 PM EasternExagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AutoZone's Pullback Sets Up a Long-Term Buying Opportunity AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus Powerhouse Williams-Sonoma Heading to Fresh Highs in 2026 Quantum Stocks Just Got a Lifeline—Who Benefits Most? Why BJ’s Wholesale Club Stock Could Be Ready for a Rebound 5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade Rocket Companies Turns Around, But Mortgage Risk Remains After NVIDIA, Broadcom's Earnings Are Next—Here's What to Watch Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
